GP2D Xenograft Model Overview
The GP2D xenograft model is derived from a human colorectal adenocarcinoma cell line originally established from a primary colon tumor of a Japanese male patient. This model exhibits features of moderately differentiated colorectal epithelium and is distinguished by its wild-type KRAS status and preserved epithelial phenotype. The GP2D xenograft is used in translational oncology to evaluate EGFR-targeted therapies, epithelial-specific drug responses, and the modulation of cell–cell adhesion signaling pathways. As a microsatellite-stable (MSS) model with consistent tumor growth and histological fidelity, GP2D is suitable for monotherapy and combination studies in colorectal cancer that aim to emulate treatment-naïve or early-stage tumor biology. The model’s capacity to support longitudinal pharmacodynamic investigations and detailed molecular profiling makes it a valuable tool in preclinical research.
Request a Custom Quote for GP2D Xenograft ModelBiological and Molecular Characteristics
GP2D cells maintain epithelial monolayer morphology with organized tight junctions and high levels of E-cadherin expression. The line is microsatellite stable (MSS) and carries wild-type alleles of KRAS, NRAS, and BRAF, rendering it responsive to EGFR-targeted monoclonal antibodies. TP53 is mutated, which may influence response to DNA-damaging agents, but does not interfere with upstream receptor pathway responsiveness. GP2D expresses moderate levels of carcinoembryonic antigen (CEA) and cytokeratin 20 (CK20), confirming its colorectal epithelial identity. The cell line also exhibits moderate proliferative capacity and retains membrane-localized β-catenin, suggesting intact Wnt signaling regulation. These characteristics support its use in targeted therapy studies, particularly in biomarker-driven patient stratification approaches.
| Characteristic | GP2D Cell Line Profile |
|---|---|
| Tissue of Origin | Colorectal adenocarcinoma (primary) |
| KRAS/NRAS/BRAF Status | Wild-type |
| TP53 Status | Mutated |
| MSI Status | Microsatellite stable (MSS) |
| Differentiation Markers | E-cadherin, CK20, CEA |
| Wnt Signaling | Active, β-catenin predominantly membranous |
In Vivo Model Development and Tumorigenicity
GP2D xenografts are established by subcutaneous implantation of cultured cells into immunodeficient mouse strains such as athymic nude or NOD/SCID mice. Tumor formation typically occurs within 10 to 14 days, with measurable volumes developing progressively over a 4- to 6-week period. Tumors generally reach 700–900 mm³ in untreated cohorts by days 30 to 40 post-implantation. The moderate and reproducible tumor growth allows for extended dosing schedules, precise pharmacokinetic assessments, and histologic sampling at multiple time points. The wild-type KRAS background is ideal for testing EGFR inhibitors and other upstream signaling regulators, while the epithelial phenotype enables studies focused on adhesion-dependent drug resistance mechanisms.
Request a Custom Quote for GP2D Xenograft ModelHistopathology and Immunohistochemical Profile
GP2D xenografts form well-differentiated adenocarcinomas with organized glandular architecture, preserved epithelial polarity, and minimal central necrosis. Hematoxylin and eosin (H&E) staining reveals columnar tumor cells with apical cytoplasmic clearing and basal nuclear alignment. Immunohistochemistry confirms robust membranous E-cadherin and β-catenin expression, along with positive staining for CK20 and CEA, validating colorectal epithelial origin and differentiation. Ki-67 staining shows a moderate proliferative index, while mutant p53 accumulation is detectable in tumor cell nuclei. The absence of desmoplastic stroma and low inflammatory infiltration enhances inter-sample consistency and facilitates molecular endpoint evaluations. These features make GP2D xenografts histologically stable and well-suited for comparative efficacy studies.
Preclinical Applications and Drug Response
The GP2D xenograft model is especially relevant for preclinical evaluation of EGFR-targeted therapies such as cetuximab and panitumumab, given its KRAS/BRAF wild-type status and preserved receptor expression. It is also suitable for studies investigating epithelial adhesion-related mechanisms of drug resistance, including therapies modulating E-cadherin/β-catenin signaling. TP53 mutation may influence response to certain genotoxic agents, though the overall moderate proliferation rate and epithelial organization support its use in long-term studies. GP2D is commonly employed in pharmacodynamic assays, tissue-based biomarker discovery, and combination therapy regimens aimed at overcoming resistance to single-agent EGFR blockade. Its predictable growth pattern, MSS phenotype, and consistent histopathology contribute to its growing role in modern colorectal cancer research.
Request This Model
To access the GP2D xenograft model for preclinical evaluation of colorectal cancer therapies, contact our scientific team to customize your study design and request detailed model specifications.
Request a Custom Quote for GP2D Xenograft Model